2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 404

Gut Microbiota Modify Inflammatory Arthritis through Autoantibody Generation and Mucosal Cytokines Alteration
Abstract Number: 405

Dynamics of Transcriptional Signatures from Purified Synovial Macrophage Subsets during Acute and Chronic Murine Models of Inflammatory Arthritis
Abstract Number: 406

Mapping Changes in Monocyte and Macrophage Populations in the Synovium: An Aging Study in Arthritic KRN Ag7 Mice
Abstract Number: 407

Selective Inhibition of Tfh Cells By a Small Molecule Inhibitor Abrogates Progression of Experimental Inflammatory Arthritis
Abstract Number: 408

CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis
Abstract Number: 409

An Evaluation of Absolute Neutrophil Count As a Biomarker of Inflammatory and Clinical Disease Activity in Baricitinib-Treated Patients
Abstract Number: 410

Association between Anti-Citrullinated Protein Antibody Status and the Incidence of Erosive Disease in Patients with RA
Abstract Number: 411

Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience
Abstract Number: 412

Baseline Values for Plantar Pressure and Background Characteristics As Indicators for the Limit of Conservative Treatment of Rheumatoid Forefoot Deformity
Abstract Number: 413

Economic Burden Associated with Anti-Cyclic Citrullinated Peptide Antibody Positivity in Patients Newly Diagnosed with RA
Abstract Number: 414

Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission
Abstract Number: 415

Baricitinib Reduces GlycA Levels in Phase 2 and Phase 3 Clinical Trials in Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 416

The Impact of Therapy on Anti-Carbamylated Protein Antibody Isotypes and Serostatus in Patients with Early RA Treated with Abatacept and MTX
Abstract Number: 417

Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan
Abstract Number: 418

Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].